World s First Intranasal COVID-19 Vaccine Gets CDSCO Approval
Phase-III trials to evaluate safety and immunogenicity of the intranasal COVID-19 vaccine were conducted in about 3100 participants in 14 trial sites across India.
Phase-III trials to evaluate safety and immunogenicity of the intranasal COVID-19 vaccine were conducted in about 3100 participants in 14 trial sites across India.
Bharat Biotech has completed phase III trials for its intranasal COVID-19 vaccine candidate, called BBV154. It's likely to receive regulatory licenses this month.
US FDA approves Moderna And Pfizer COVID-19 vaccines for children under 5, Bharat Biotech confirms safety of Covaxin for 2-year-olds.
Bharat Biotech had sought permission from DCGI to conduct the phase-3 study in December 2021. The trials would be conducted at nine different sites, including AIIMS Delhi.
Two persons have tested positive for Omicron variant in Karnataka. Both patients have travel history to South Africa.
Last month, the UK government had added Covishield to its list of approved vaccines for for international travellers. COVAXIN will also be added to the list from November 22.
The shelf life of indigenously-developed Covaxin has been further extended to 12 months. WHO has also approved global use of the vaccine developed by Bharat Biotech.
Bharat Biotech last month said it has submitted all data pertaining to Covaxin to the WHO for EUL and is awaiting feedback from the global health watchdog.
Johnson and Johnson's single-dose COVID-19 vaccine has already been approved for the emergency use in adult population (those aged 18 and above) in India.
Covaxin is the only vaccine to have demonstrated efficacy against the Delta variant in Phase 3 human clinical trials, says Bharat Biotech.
Rotavirus vaccine is considered the best way to protect children against rotavirus disease, which causes severe, watery diarrhea and vomiting.
Bharat Biotech is working on a nasal vaccine, which is expected to be launched by the end of the year. Read on to know the benefits of intranasal Covid-19 vaccines.
According to the company's chairman, just one drop of vaccine in each of the nostrils is sufficient, and to administer the dose one doesn`t require trained healthcare workers.
Notably, India approved two vaccines - Covishield and Covaxin - on January 3, paving way for mass vaccination drive in the country, which has the second highest number of infections in the world.
The first batch of Covaxin has been sent to the Central Research Institute (CRI) in Kasauali for further distribution, Bharat Biotech's CMD Dr Krishna Ella said on Monday.
DCGI came under flak from various quarters for approving Covaxin even before the completion of Phase 3 trials. Bharat Biotech has put all the concerns to rest and refuted criticism.
India is likely to approve a Covid-19 vaccine for emergency use next week. Both Serum Institute of India (SII) and Bharat Biotech have submitted additional data sought by the DCGI for grant of emergency use authorisation to their vaccines.
Hyderabad-based Bharat Biotech began phase-3 human clinical trials of its COVID-19 vaccine, called Covaxin, in mid-November targeting 26,000 volunteers. So far, 13,000 volunteers have received the vaccine across the country, the company said.
Phase-III trials to evaluate safety and immunogenicity of the intranasal COVID-19 vaccine were conducted in about 3100 participants in 14 trial sites across India.
Bharat Biotech has completed phase III trials for its intranasal COVID-19 vaccine candidate, called BBV154. It's likely to receive regulatory licenses this month.
US FDA approves Moderna And Pfizer COVID-19 vaccines for children under 5, Bharat Biotech confirms safety of Covaxin for 2-year-olds.
Bharat Biotech had sought permission from DCGI to conduct the phase-3 study in December 2021. The trials would be conducted at nine different sites, including AIIMS Delhi.
Two persons have tested positive for Omicron variant in Karnataka. Both patients have travel history to South Africa.
Last month, the UK government had added Covishield to its list of approved vaccines for for international travellers. COVAXIN will also be added to the list from November 22.
The shelf life of indigenously-developed Covaxin has been further extended to 12 months. WHO has also approved global use of the vaccine developed by Bharat Biotech.
Bharat Biotech last month said it has submitted all data pertaining to Covaxin to the WHO for EUL and is awaiting feedback from the global health watchdog.
Johnson and Johnson's single-dose COVID-19 vaccine has already been approved for the emergency use in adult population (those aged 18 and above) in India.
Covaxin is the only vaccine to have demonstrated efficacy against the Delta variant in Phase 3 human clinical trials, says Bharat Biotech.
Rotavirus vaccine is considered the best way to protect children against rotavirus disease, which causes severe, watery diarrhea and vomiting.
Bharat Biotech is working on a nasal vaccine, which is expected to be launched by the end of the year. Read on to know the benefits of intranasal Covid-19 vaccines.
According to the company's chairman, just one drop of vaccine in each of the nostrils is sufficient, and to administer the dose one doesn`t require trained healthcare workers.
Notably, India approved two vaccines - Covishield and Covaxin - on January 3, paving way for mass vaccination drive in the country, which has the second highest number of infections in the world.
The first batch of Covaxin has been sent to the Central Research Institute (CRI) in Kasauali for further distribution, Bharat Biotech's CMD Dr Krishna Ella said on Monday.
DCGI came under flak from various quarters for approving Covaxin even before the completion of Phase 3 trials. Bharat Biotech has put all the concerns to rest and refuted criticism.
India is likely to approve a Covid-19 vaccine for emergency use next week. Both Serum Institute of India (SII) and Bharat Biotech have submitted additional data sought by the DCGI for grant of emergency use authorisation to their vaccines.
Hyderabad-based Bharat Biotech began phase-3 human clinical trials of its COVID-19 vaccine, called Covaxin, in mid-November targeting 26,000 volunteers. So far, 13,000 volunteers have received the vaccine across the country, the company said.